Clinical Trial Update: Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating trilaciclib to prevent myelosuppression in limited-stage small cell lung cancer; status shows not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Cosela (trilaciclib)

Snippet

Sponsor: Pharmacosmos A/S | Conditions: Limited Stage Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING